AMMONIA N 13

Post-LOE

ammonia n-13

Precision BioSciences

ANDAINTRAVENOUSINJECTABLE

Approved

Aug 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

AMMONIA N 13 (ammonia n-13) by Precision BioSciences is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 2015.

Drug data last refreshed 20h ago

Mechanism of Action

Radiopharmaceutical Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Indications (1)

Radioactive Diagnostic Agent

Clinical Trials (1)

NCT04343209N/ACompleted

Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)

Started Sep 2020

170 enrolled

Myocardial IschemiaCoronary DiseaseCoronary Artery Disease+5 more

Company

Worked on AMMONIA N 13 at Precision BioSciences? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.